Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis

EJ Soini, TA Hallinen, K Puolakka, V Vihervaara, MJ Kauppi

    Research output: Contribution to journalArticleScientificpeer-review

    41 Citations (Scopus)
    Original languageEnglish
    Pages (from-to)340-351
    JournalJournal of Medical Economics
    Volume15
    Issue number2
    Publication statusPublished - 2012
    Publication typeA1 Journal article-refereed

    Cite this